Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olorinab Effect on GI Transit in IBS
NCT04655599Phase 1Terminated
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olorinab in irritable bowel syndrome (IBS) (2 arms), sponsored by Arena Pharmaceuticals, Inc. Primary endpoints: Colonic transit geometric center after consumption of radiolabeled meal and Gastric emptying half-life (t½). Started Jan 2021; status: terminated.
02
Drugs
olorinab
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT04655599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655599.